ClinicalTrials.gov
public full text
Public Domain
Value of Rituximab in Humoral Chronic Rejection After Renal Transplantation
To evaluate the benefit of rituximab in patients with CAN with histologically proven C4d deposits and/or plasma cell and/or B-Lymphocyte (CD20+ cells) infiltration of their grafts.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Rituximab Therapy for Patients on Kidney Transplant Waiting List With Positive Donor Specific Crossmatch to Living Donor#915219
- Successful Use of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy with Lisocabtagene Maraleucel in a Renal Transplant Recipient with Refractory/Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)#219205
- Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Crossmatch Deceased Donor Kidney Transplant#1171525
- Response to Influenza Vaccination in Lymphoma Patients Treated With Rituximab#1396667
- Rituximab and DexaBEAM as Salvage Therapy for Relapsed Lymphoma#1382585
Record · ID 1407797
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive